Reddit Posts
Favorite mid-cap biotech with the most upside? (500M–2.5B mkt cap)
NurExone Biologic (NRX): A Biotech Stock Turning Heads in 2025
NurExone Biologic (NRX): A Biotech Stock Turning Heads in 2025
NurExone Biologic (NRX): A Biotech Stock Turning Heads in 2025
RGNX 🚀Breaking off the Lows Big Time , Low Float of Shares 38M , 13.58% Shorts are Covering ASAP
🏦 RGNX 🏦🚀🚀🚀 Holding Strong in Down Market,against the Tariff Sell off.Undervalued 3 Block Busters Drugs in Phase 3.Low Float of Shares & 13% Short Interest. Potentially Could 3X..
RGNX 🚀🚀Biotech; Has Tremendous 3X Potential, Low Float of Shares 41.06M
RGNX 🚀🚀 Potentially Could Easily 3X Low Float of Shares 41.06 , Break Points 50 Day Mvn Avg $7.11 / 200Day Mvn Avg$9.50
$ABBV short term calls Gain with more to come after Friday announcement with RGNX! Here we go!!!
Mentions
🟢 $SLND +62.9% (Winnipeg waste project JV) 🟢 $SDOT +50.1% (Mystery pump on 652k float) 🟢 $CJMB +42.8% (ASU pharmaceutical partnership) 🔴 $RGNX -19.5% (Proposed dilutive offering) 🔴 $CYCU -15.0% (Nasdaq delisting appeal)
I have ONDS but not RCAT. I don’t have much in biotech except for RGNX and IOVA
Obviously the PSKY WBD NFLX drama will dominate. But the QURE and RGNX thing is so compelling, with actual life and death consequences. Market is saying RGNX is in the clear and QURE is finished but I’m taking the contrarian play.
RGNX to the freaking 🌕
Im holding RGNX and HURA waiting for catalysts next week and Feb. 8th. Gonna 3x my day treading account on these 2 hopefully.
RGNX February 8. It's not listed and it's more explosive. Target price $31-32 and a month ahead for significant gains.
RGNX for tomorrow, 02.12.2025
Dont sleep on RGNX either!
Check out RGNX. They are also presenting and super undervalued.
That RGNX I purchase randomly awhile ago is finally doing something.
Anyone have an opinion on RGNX?
Thoughts on RGNX ? I have 475 shares sell or hold?
Maybe I will try some RGNX while I am at it bc the partnership is with ABBV.
Hahaha screw fraudulent earnings $RGNX make shorts suffer Target 100 bucks
$RGNX make shorts suffer Target 100 bucks Scalp paloooza
I'd say stop trying to chase profits and worrying about under-performing. If you have an investment strategy, which allegedly has 5x'd your money in what couldn't have been more than a couple years, then stick to it. Don't let the market shake you out of your trade just because you're 'underperforming' if you have conviction in it. I let that happen to me numerous times, and almost every time I regretted it immensely, as what I thought was going to happen happened **exactly** as I thought it would. The most troublesome case of this was in early 2020 when I understood the implications of covid and saw the writing on the wall in January, yet actually lost money in the end because of flip-flopping off the trade. With that being said, I don't get why you'd be so heavily into ARK ETF's and it makes me think you DON'T actually have an investment strategy. Fix that. If you want to invest in genome companies, because you believe it to be the future of medicine, great. Feel free to buy some CRSP, buy some IONS, buy some RGNX, maybe some ARKG, buy whatever you'd like - and stick to it - but don't so just to follow others who have fomo. If you are actually tired of playing them market, and don't believe in anything in particular, then index funds are probably best - as they are for most people - but if you are just saying that because you've underperformed recently you'll sell those funds in a couple months and be right back to it - likely kicking yourself for 'giving up' on a trade too soon, as I once was.
Well, he seems to be better than the last two CEOs. Have heard him speak, and he seems to be able to tell the story to the investment community better than either Carsten Thiel or Joao Siffert (last two "CEO"s). Had some Celgene backround, which is positive. Clinical data speaks for itself - lead three programs in RDEB, MPS IIIA and MPS IIIB all seem to convene meaningful clinical benefit with benign/acceptable risk profiles, and are well ahead of any competition in those indications. I think it would be a great (and inexpensive at even a 100% premium) tuck-in acquisition for multiple gene therapy/rare disease companies like RARE, QURE, RGNX, SRPT, and the big biotechs/pharmas that have made in-roads into gene therapy like Novartis (bought AveXis), Roche (bought Spark), Biogen, Astellas, etc. Need a new investor relations program and get Amoroso out on the road telling the story.